Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults With Fragile X Syndrome

NCT03802799 is registered in ClinicalTrials.gov with Zynerba Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03802799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults With Fragile X Syndrome
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 9, 2018
Completion date
June 30, 2026
Enrollment
476 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome